Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis
- PMID: 22730417
- PMCID: PMC3508293
- DOI: 10.1002/acr.21764
Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis
Abstract
Objective: To estimate the incidence and risk factors for gastrointestinal (GI) perforation among patients with rheumatoid arthritis (RA).
Methods: Claims from employer health insurance plans were used to identify RA patients and those hospitalized for upper or lower GI perforation. GI perforation cases were identified using both a sensitive and a specific definition. A Cox model using fixed and time-varying covariates was used to evaluate the risk of GI perforation.
Results: Among 143,433 RA patients, and using a maximally sensitive GI perforation definition, 696 hospitalizations with perforation were identified. The rate of perforation was 1.70 per 1,000 person years (PYs; 95% confidence interval [95% CI] 1.58-1.83), and most perforations (83%) occurred in the lower GI tract. The rate of perforation was lower when a more specific GI perforation definition was used (0.87; 95% CI 0.78-0.96 per 1,000 PYs). Age and diverticulitis were among the strongest risk factors for perforation (diverticulitis hazard ratio [HR] 14.5 [95% CI 11.8-17.7] for the more sensitive definition, HR 3.9 [95% CI 2.5-5.9] for the more specific definition). Among various RA medication groups and compared to methotrexate, the risk of GI perforation was highest among patients with exposure to nonsteroidal antiinflammatory drugs (NSAIDs), concomitant nonbiologic disease-modifying antirheumatic drugs, and glucocorticoids. Biologic agents without glucocorticoid exposure were not a risk factor for perforation.
Conclusion: GI perforation is a rare but serious condition that affects patients with RA, most frequently in the lower GI tract. Clinicians should be aware of risk factors for GI perforation when managing RA patients, including age, history of diverticulitis, and use of glucocorticoids or NSAIDs.
Copyright © 2012 by the American College of Rheumatology.
Conflict of interest statement
Dr. Curtis receives support from the NIH (AR053351) and AHRQ (R01HS018517). He has received grant/research support and been a consultant for UCB, Centocor, CORRONA, Amgen, Pfizer, BMS, Crescendo, Abbott, and Genentech, a member of the Roche group. Angel Lanas has been a member of the Adjudication Committee of the international multicenter CONDOR trial sponsored by Pfizer and a consultant to AstraZeneca and Genentech, a member of the Roche group. Ani John is an employee of Genentech, a member of the Roche group. David Johnson and Kathy Schulman are consultants to Genentech, a member of the Roche group.
Similar articles
-
[Incidence rates and risk factors for gastrointestinal perforation in patients with rheumatoid arthritis].Z Rheumatol. 2014 Feb;73(1):85-6. doi: 10.1007/s00393-013-1277-8. Z Rheumatol. 2014. PMID: 24306840 German. No abstract available.
-
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.Arthritis Rheum. 2011 Feb;63(2):346-51. doi: 10.1002/art.30107. Arthritis Rheum. 2011. PMID: 20967860 Free PMC article.
-
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.Arthritis Rheumatol. 2016 Nov;68(11):2612-2617. doi: 10.1002/art.39761. Arthritis Rheumatol. 2016. PMID: 27213279 Free PMC article.
-
Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.Clin Rheumatol. 2011 Nov;30(11):1471-4. doi: 10.1007/s10067-011-1827-x. Epub 2011 Aug 11. Clin Rheumatol. 2011. PMID: 21833686 Review.
-
Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.Drug Saf. 2018 Jun;41(6):545-553. doi: 10.1007/s40264-018-0639-1. Drug Saf. 2018. PMID: 29392593 Review.
Cited by
-
Impact of upadacitinib on the risk of digestive events in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials.Heliyon. 2023 Jun 4;9(6):e17002. doi: 10.1016/j.heliyon.2023.e17002. eCollection 2023 Jun. Heliyon. 2023. PMID: 37484342 Free PMC article.
-
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.Rheumatology (Oxford). 2023 Oct 3;62(10):3268-3279. doi: 10.1093/rheumatology/kead062. Rheumatology (Oxford). 2023. PMID: 36727470 Free PMC article.
-
Comparison of the risk of gastrointestinal perforation between patients with and without rheumatoid arthritis: A nationwide cohort study in Asia.Front Med (Lausanne). 2022 Sep 29;9:974328. doi: 10.3389/fmed.2022.974328. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36250072 Free PMC article.
-
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.Adv Ther. 2022 Nov;39(11):4910-4960. doi: 10.1007/s12325-022-02281-4. Epub 2022 Sep 5. Adv Ther. 2022. PMID: 36063279 Free PMC article. Review.
-
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure.RMD Open. 2021 May;7(2):e001595. doi: 10.1136/rmdopen-2021-001595. RMD Open. 2021. PMID: 34045358 Free PMC article.
References
-
- Cafardi J, Rakatansky H, Alarcón G. Gastrointestinal manifestations of rheumatoid arthritis. In: Asherson R, Font J, Ramos-Casals M, Rodés J, editors. Handbook of Systemic Autoimmune Diseases. Vol. 8. Amsterdam: Elsevier BV; 2008. pp. 109–117.
-
- Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62(6):1592–1601. - PubMed
-
- Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115–123. - PubMed
-
- Humes DJ, Fleming KM, Spiller RC, West J. Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study. Gut. 2011;60(2):219–224. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
